Needham analyst Michael Matson maintained a Hold rating on Cardiovascular Systems (NASDAQ: CSII) today. The company’s shares closed yesterday at $23.29.
Matson commented:
“CSII’s F3Q18 revenue met consensus while EPS beat consensus. Management’s F4Q18 revenue guidance bracketed consensus while EPS guidance was above consensus. The F4Q18 revenue guidance requires a substantial acceleration from F3Q18 but we note that CSII faces a significantly easier revenue growth comp in F4Q18 than in F3Q18 (9.2% vs. 17.3%). Looking into FY19, CSII should continue to benefit from the Japanese launch, new support products, building rep productivity, and a further easing of comps so we think it can see its revenue growth accelerate further. However, it remains to be seen if CSII can sustain double- digit revenue growth and considering its 3.0x 2018E EV/sales multiple, we maintain our Hold rating.”
According to TipRanks.com, Matson is a 5-star analyst with an average return of 8.6% and a 59.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Merit Medical Systems.
Cardiovascular Systems has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
The company has a one-year high of $33.11 and a one-year low of $20.58. Currently, Cardiovascular Systems has an average volume of 288.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cardiovascular Systems, Inc. is a medical device company, which develops and sells devices for treating cardiovascular diseases. It focuses on developing and commercializing minimally invasive treatment solutions for vascular diseases.
